Immuron Limited IMRN
Annual
Quarterly
No annual revenue total was found in IMMURON LIMITED's SEC filings.
Immuron Limited (IMRN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
$-1.25
Dividend per share
None
Shares outstanding
322.85M
+38.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMRN (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Carlton, Victoria, Australia
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1660046
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2022 Jun 30, 2022 |
|---|---|
| Diluted EPS | -$1.25 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 28, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 23, 2026 | Oct 23, 2026 |
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Oct 16, 2026 | Oct 16, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
All 427 Immuron Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.